Intensity Therapeutics, Inc.
INTS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | -$0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $10 | $5 | $5 | $6 |
| G&A Expenses | $6 | $4 | $2 | $2 |
| SG&A Expenses | $6 | $3 | $2 | $2 |
| Sales & Mktg Exp. | $0 | -$0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $17 | $8 | $8 | $8 |
| Operating Income | -$17 | -$8 | -$8 | -$8 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | -$2 | -$0 | $0 |
| Pre-Tax Income | -$16 | -$11 | -$8 | -$8 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$16 | -$11 | -$8 | -$8 |
| % Margin | – | – | – | – |
| EPS | -1.17 | -0.87 | -0.58 | -0.6 |
| % Growth | -34.5% | -50% | 3.3% | – |
| EPS Diluted | -1.17 | -0.87 | -0.58 | -0.6 |
| Weighted Avg Shares Out | 14 | 14 | 13 | 13 |
| Weighted Avg Shares Out Dil | 14 | 14 | 13 | 13 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$16 | -$10 | -$8 | -$8 |
| % Margin | – | – | – | – |